Compare ODC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | CMPS |
|---|---|---|
| Founded | 1941 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 1994 | 2020 |
| Metric | ODC | CMPS |
|---|---|---|
| Price | $100.25 | $13.68 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.38 |
| AVG Volume (30 Days) | 119.8K | ★ 3.3M |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 50.45 | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $59.37 | ★ N/A |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $45.61 | $3.25 |
| 52 Week High | $106.84 | $15.40 |
| Indicator | ODC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 70.98 | 58.42 |
| Support Level | $70.50 | $5.57 |
| Resistance Level | N/A | $14.76 |
| Average True Range (ATR) | 3.37 | 0.96 |
| MACD | 0.07 | 0.05 |
| Stochastic Oscillator | 56.43 | 58.12 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.